Acute
heart failure (AHF) is a progressive condition, in which, the heart
muscle is unable to pump enough blood through the heart to meet body’
optimal blood and oxygen level. Congestive heart failure is type of
heart failure which requires timely medical attention. Moreover,
distinguish between acute and chronic heart failure is important from
a clinical standpoint, on which further medication depends. For this,
N terminal proB-type natriuretic peptide levels are used for
distinguishing acute versus chronic left ventricular dysfunction. An
elevated levels of natriuretic peptide were present in patients with
acute heart failure compared to those with chronic heart failure
patient.
Heart
failure symptoms vary widely from person to person, depending on
types of heart failure patient. The main symptoms of heart failure
are caused due to fluid accumulation or congestion and poor blood
flow to the body. Symptoms caused by fluid accumulation or congestion
includes shortness of breath, weight gain, coughing, swollen ankles,
legs or abdomen, while dizziness, rapid heart rate, and fatigue are
symptoms associated with reduced blood flow to parts of the body.
Get
FREE In-Depth Sample Copy of Research @
https://www.coherentmarketinsights.com/insight/request-sample/1910
Acute
Heart Failure (AHF) Therapeutics Market – Drivers
The
global acute heart failure therapeutics market is expected to witness
significant growth due to approval of new drugs. For instance, in
July 2015, Novartis received U.S. Food and Drug Administration (FDA)
approval for their Entresto(TM) (sacubitril/valsartan) tablets on the
treatment of heart failure with reduced ejection fraction. Entresto
is indicated to reduce the risk of cardiovascular death and heart
failure hospitalization.
Furthermore,
robust pipeline of drugs over the forecast period (2018-2026), is
another factor driving growth of acute heart failure therapeutics
market. For instance, in March 2017, Cardioxyl Pharmaceuticals’
CXL-1427: a novel nitroxyl (HNO) donor (prodrug), which now operates
under the Bristol-Myers Squibb Company (after Cardioxyl
Pharmaceuticals’ acquisition by Bristol-Myers Squibb in December
2015); is present in Phase 2 clinical development phase. CXL-1427 is
indicated to use as an intravenous treatment for acute decompensated
heart failure (ADHF). Successful completion and further launch of
Bristol-Myers Squibb’s innovative drug in future, will help to
boost the acute heart failure (AHF) therapeutics market growth during
the forecast period.
Acute
Heart Failure (AHF) Therapeutics Market – Regional Analysis
Geographically,
the market is segmented into North America, Latin America, Europe,
Middle East, Asia Pacific, and Africa. North America is expected to
hold dominant position in global acute heart failure (AHF)
therapeutics market, due to high prevalence of acute heart failure
cases, in this region. For instance, according to Centers for Disease
Control and Prevention (CDC), June 2016, around 5.7 million adults in
the U.S. suffered from heart failure, in 2016. Moreover, about half
of the people who develop heart failure die within 5 years of
diagnosis.
Acute
Heart Failure (AHF) Therapeutics Market – Competitive Landscape
Some
of the key players in this market are Novartis AG, Cardiorentis AG,
Bristol-Myers Squibb Company, Amgen Inc., Bayer AG, Cytokinetics,
Inc., Merck & Company, Inc., Ono Pharmaceutical Co., Ltd., and
Pfizer Inc., among others. Key players in the marker are engaged in
development of new drugs for acute heart failure (AHF). These players
are incorporating collaboration strategies to remain competitive in
the market.
Acute
Heart Failure (AHF) Therapeutics Market – Taxonomy
By
Disorder Type:
Right-sided
Heart Failure
Left-sided
Heart Failure: Systolic Failure, Diastolic Failure
Congestive
Heart Failure
Request
For Customization of This Exclusive Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/1910
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment